ClinicalTrials.gg
Sign In

Drug

Anti-EGFR Antibody-drug Conjugate CPO301 clinical trials

Also written SYS6010.

studies test it
16
open now
15
in phase 3
9
first study started
2023

Keep track of what changes. Save the Anti-EGFR Antibody-drug Conjugate CPO301 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

SYS6010 injection
2

Development codes

SYS6010
11
CPO301
1

Combined with it in one product

SYS6090 + SYS6010
1
SYS6010+SG001
1

Studies by the year they started

16 studies that test it; most in 2026 (9)

Studies that test Anti-EGFR Antibody-drug Conjugate CPO301, by start year
YearStudies
20231
20241
20255
20269

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
5
Phase 3
9
No phase
1

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Non-Small-Cell Lung
6
Squamous Cell Carcinoma of Head and Neck
2
Breast Neoplasms
2
Colorectal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Lung Neoplasms
1

Who runs them

Industry 14 · Other 2

CSPC Megalith Biopharmaceutical Co.,Ltd. (12) · Fujian Cancer Hospital (1) · Sichuan University (1) · Shanghai JMT-Bio Inc. (1) · Conjupro Biotherapeutics, Inc. (1)

Often tested with

Tested in the same studies.

Enlonstobart (3) · ATM Inhibitor SYH2051 (2) · Anti-PD-1/IL-15 Fusion Protein JMT108 (1) · Pemetrexed (1) · Paclitaxel (1) · Docetaxel (1) · Bevacizumab (1) · Etoposide (1)

Studies

Open first, then newest update. How each study uses Anti-EGFR Antibody-drug Conjugate CPO301 is read from its arms, and is right about nine times in ten.

Testing it · 16

Given in every arm · 1 — Anti-EGFR Antibody-drug Conjugate CPO301 is usual care beside what is tested